Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.
Post-Conference Perspectives: Uveal Melanoma
Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.
Dr Ryan Sullivan details clinical trial data presented at ASCO 2022 on the use of tebentafusp for mUM.
Experts highlight strategies for managing the adverse events of tebentafusp, especially cytokine release syndrome.
Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5